KR100944600B1 - 치환된 퀴노벤족사진 유사체 - Google Patents

치환된 퀴노벤족사진 유사체 Download PDF

Info

Publication number
KR100944600B1
KR100944600B1 KR20057019057A KR20057019057A KR100944600B1 KR 100944600 B1 KR100944600 B1 KR 100944600B1 KR 20057019057 A KR20057019057 A KR 20057019057A KR 20057019057 A KR20057019057 A KR 20057019057A KR 100944600 B1 KR100944600 B1 KR 100944600B1
Authority
KR
South Korea
Prior art keywords
compound
mmol
alkyl
optionally substituted
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR20057019057A
Other languages
English (en)
Korean (ko)
Other versions
KR20060029210A (ko
Inventor
제프리 피. 위튼.
마이클 슈애베
아담 시디퀴-자인
테란스 모란
Original Assignee
사일린 파마슈티칼스, 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사일린 파마슈티칼스, 인크 filed Critical 사일린 파마슈티칼스, 인크
Publication of KR20060029210A publication Critical patent/KR20060029210A/ko
Application granted granted Critical
Publication of KR100944600B1 publication Critical patent/KR100944600B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR20057019057A 2003-04-07 2004-04-07 치환된 퀴노벤족사진 유사체 Expired - Fee Related KR100944600B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US46127103P 2003-04-07 2003-04-07
US60/461,271 2003-04-07
US46317103P 2003-04-15 2003-04-15
US60/463,171 2003-04-15
US51953503P 2003-11-12 2003-11-12
US60/519,535 2003-11-12
US53272703P 2003-12-23 2003-12-23
US60/532,727 2003-12-23

Publications (2)

Publication Number Publication Date
KR20060029210A KR20060029210A (ko) 2006-04-05
KR100944600B1 true KR100944600B1 (ko) 2010-02-25

Family

ID=33304104

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20057019057A Expired - Fee Related KR100944600B1 (ko) 2003-04-07 2004-04-07 치환된 퀴노벤족사진 유사체

Country Status (11)

Country Link
US (5) US7141565B1 (enExample)
EP (1) EP1610759A4 (enExample)
JP (1) JP2006522827A (enExample)
KR (1) KR100944600B1 (enExample)
AU (1) AU2004229489B2 (enExample)
BR (1) BRPI0409105A (enExample)
CA (1) CA2521810A1 (enExample)
MX (1) MXPA05010776A (enExample)
NO (1) NO20054669L (enExample)
NZ (1) NZ543006A (enExample)
WO (1) WO2004091504A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543006A (en) * 2003-04-07 2009-03-31 Cylene Pharmaceuticals Inc Substituted quinobenzoxazine analogs
US7354916B2 (en) * 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
US7507727B2 (en) 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
US20080032286A1 (en) * 2003-10-14 2008-02-07 Cylene Pharaceuticals, Inc. Competition Assay for Identifying Modulators of Quadruplex Nucleic Acids
DE102004035203A1 (de) * 2004-07-21 2006-02-16 Bayer Healthcare Ag Substituierte Chinolone
MX2007003282A (es) * 2004-09-17 2007-10-16 Cylene Pharmaceuticals Inc Analogos de quinolona.
US7652134B2 (en) * 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
CA2604787A1 (en) * 2005-04-15 2006-10-26 Cylene Pharmaceuticals, Inc. Quinobenzoxazine analogs and methods of using thereof
US7610985B2 (en) * 2005-05-18 2009-11-03 Kanzaki Kokyukoki Mfg. Co., Ltd. HST unit
DE102006005861A1 (de) 2006-02-09 2007-08-23 Aicuris Gmbh & Co. Kg Substituierte Chinolone III
US8481529B2 (en) * 2006-05-16 2013-07-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Combination cancer chemotherapy
EP2023935A4 (en) * 2006-06-03 2010-12-22 Cylene Pharmaceuticals Inc METHODS OF DRUG DELIVERY
US8410070B2 (en) * 2008-09-12 2013-04-02 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer, inhibiting proliferation, and inducing cell death
US8470817B2 (en) 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
US9730609B2 (en) * 2011-12-15 2017-08-15 Siemens Healthcare Gmbh Method and system for aortic valve calcification evaluation
JP6249436B2 (ja) * 2012-08-31 2017-12-20 国立大学法人東京農工大学 四重らせんｄｎａ検出プローブ及びそれを用いた四重らせん構造の検出方法
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
CA2948173C (en) 2014-05-09 2018-06-19 Pimera, Inc. Quinoline compounds and uses thereof
CN110709400A (zh) 2017-03-28 2020-01-17 皮梅拉股份有限公司 Pol1抑制剂的新型晶体形式
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
CN114716373B (zh) * 2022-04-14 2023-01-10 内蒙古源宏精细化工有限公司 一种加替沙星环合酯的制备方法
CN116023263A (zh) * 2022-11-17 2023-04-28 苏州汉德创宏生化科技有限公司 一种中间体3-(3,5-二氯苯基)-3-氧代丙酸乙酯的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162333A1 (en) * 1984-04-26 1985-11-27 Abbott Laboratories Quino-benzothiazine antibacterial compounds
US4977263A (en) * 1986-01-15 1990-12-11 Bayer Aktiengesellschaft Process for preparing 1,8-bridged 4-quinolone-3-carboxylic acid antibacterials
US5318965A (en) * 1990-08-24 1994-06-07 Abbott Laboratories Quinobenzoxazine, antineoplastic agents

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
CA1267413A (en) * 1984-04-26 1990-04-03 Abbott Laboratories Quino-benoxazine antibacterial compounds
US4607032A (en) * 1984-04-26 1986-08-19 Abbott Laboratories Quino-benoxazine antibacterial compounds
US4533663A (en) 1984-04-26 1985-08-06 Abbott Laboratories Quino-benzothiazine antibacterial compounds
US4528285A (en) * 1984-04-26 1985-07-09 Abbott Laboratories Methylenedioxy quino-benzothiazine derivatives
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
JPH0240379A (ja) 1988-07-28 1990-02-09 Wakunaga Pharmaceut Co Ltd 新規キノロン誘導体
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IE912902A1 (en) 1990-08-24 1992-02-26 Abbott Lab Quinbenzoxazine, quinobenzothiazine, and pyrido-acridine¹antineoplastic agents
US5225418A (en) 1991-12-17 1993-07-06 Du Pont Merck Pharmaceutical Company 5H-(1,2)benzisothiazolo[2,3-a]quinoline-5-ones and analogs as antiinflammatory agents
ATE357663T1 (de) 1996-04-25 2007-04-15 Genicon Sciences Corp Teilchenförmiges markierungsmittel verwendendes analytassay
US5992478A (en) * 1996-07-08 1999-11-30 The Boc Group, Inc. Method and apparatus for filling containers with gas mixtures
WO1999040093A2 (en) * 1998-02-04 1999-08-12 Board Of Regents, The University Of Texas System Synthesis of quinobenzoxazine analogues with topoisomerase ii and quadruplex interactions for use as antineoplastic agents
US6750224B1 (en) * 1999-05-07 2004-06-15 Wockhardt Limited Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment
EP1175217B8 (en) * 1999-05-07 2009-03-18 Wockhardt Limited (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents
US20020049223A1 (en) 1999-11-05 2002-04-25 Elmore Steven W. Quinoline and naphthyridine carboxylic acid antibacterials
PT1299395E (pt) * 2000-07-12 2005-01-31 Upjohn Co Oxazinoquinolonas uteis para o tratamento de infeccoes provocadas por virus
HUP0303410A3 (en) 2000-12-14 2005-12-28 Procter & Gamble Antimicrobial quinolones, pharmaceutical compositions containing them and their use
US8163769B2 (en) 2002-03-12 2012-04-24 Abbott Laboratories Antibacterial compounds
US6818654B2 (en) 2002-03-12 2004-11-16 Abbott Laboratories Antibacterial compounds
US6900224B2 (en) 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
EP1610795A4 (en) 2003-04-07 2007-10-24 Cylene Pharmaceuticals Inc SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE HETEROCYCLIC ANALOGUES
US7354916B2 (en) * 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
NZ543006A (en) * 2003-04-07 2009-03-31 Cylene Pharmaceuticals Inc Substituted quinobenzoxazine analogs
WO2004100006A1 (en) * 2003-05-07 2004-11-18 Koninklijke Philips Electronics N.V. Processing system and method for transmitting data
US7196200B2 (en) 2004-01-21 2007-03-27 Abbott Laboratories Antibacterial compounds
JP4517731B2 (ja) * 2004-05-31 2010-08-04 日産自動車株式会社 内燃機関のコネクティングロッド設計方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162333A1 (en) * 1984-04-26 1985-11-27 Abbott Laboratories Quino-benzothiazine antibacterial compounds
US4977263A (en) * 1986-01-15 1990-12-11 Bayer Aktiengesellschaft Process for preparing 1,8-bridged 4-quinolone-3-carboxylic acid antibacterials
US5318965A (en) * 1990-08-24 1994-06-07 Abbott Laboratories Quinobenzoxazine, antineoplastic agents

Also Published As

Publication number Publication date
AU2004229489A1 (en) 2004-10-28
US20120122804A1 (en) 2012-05-17
US7326702B2 (en) 2008-02-05
JP2006522827A (ja) 2006-10-05
US20080261963A1 (en) 2008-10-23
WO2004091504A3 (en) 2006-01-05
NO20054669L (no) 2005-11-14
KR20060029210A (ko) 2006-04-05
WO2004091504A2 (en) 2004-10-28
AU2004229489B2 (en) 2010-03-04
US7381720B2 (en) 2008-06-03
US7141565B1 (en) 2006-11-28
CA2521810A1 (en) 2004-10-28
US7612063B2 (en) 2009-11-03
MXPA05010776A (es) 2006-05-25
NO20054669D0 (no) 2005-10-11
NZ543006A (en) 2009-03-31
EP1610759A2 (en) 2006-01-04
EP1610759A4 (en) 2007-04-25
US20070043039A1 (en) 2007-02-22
BRPI0409105A (pt) 2006-04-25
US20060229303A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
KR100944600B1 (ko) 치환된 퀴노벤족사진 유사체
US20110065687A1 (en) Hydrazide compounds and uses thereof
US20090215761A1 (en) Quinobenzoxazine analogs and methods of using thereof
US7816406B2 (en) Quinolone analogs
EP2214491A1 (en) Quinolone analogs and methods related thereto
US20100063046A1 (en) Tetracyclic imidazole analogs
US7507727B2 (en) Substituted quinobenzoxazine analogs and methods of using thereof
US7354916B2 (en) Substituted quinobenzoxazine analogs
US7163948B2 (en) Heterocyclic substituted 1,4-dihydri-4ox9-1,8-naphthyridine analogs
CN1809572B (zh) 取代醌苯并恶嗪类似物
RU2349586C2 (ru) Аналоги хинолона

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130220

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130220